Zhongshan KF

Akeso is a leading clinical-stage biopharmaceutical company focused on the discovery and development of innovative antibody drugs. Headquartered in Zhongshan, China, the company specializes in oncology, immunology, and other major therapeutic areas. Akeso has successfully developed a robust pipeline of next-generation therapies, including the world's first PD-1/CTLA-4 bispecific antibody, cadonilimab, and the PD-1/VEGF bispecific antibody, ivonescimab. The company utilizes its proprietary Tetrabody technology to engineer multi-specific antibodies with enhanced efficacy and safety profiles. With a fully integrated platform spanning drug discovery to commercial manufacturing, Akeso is positioned as a major player in the global biologics market.